[Skip to Content]
[Skip to Content Landing]
JAMA Network Insights
April 11, 2019

Treatment of Metastatic Urothelial Cancer in 2018

Author Affiliations
  • 1Medical Oncology Department, Hospital del Mar, IMIM (Hospital del Mar Research Institute), Barcelona, Spain
  • 2Dana-Farber Cancer Institute/Harvard Cancer Center, Harvard Medical School, Boston, Massachusetts
JAMA Oncol. 2019;5(6):904-905. doi:10.1001/jamaoncol.2019.0182

Until the advent of immune-checkpoint inhibitors (ICIs), metastatic urothelial carcinoma (mUC) has remained an aggressive disease with few treatment improvements. Cisplatin-based combinations are the standard-of-care first-line option for “fit” (able to receive cisplatin) patients and have remained so for the last 3 decades.1,2 However, this therapeutic scenario might soon change if any of the ongoing phase 3 clinical trials combining ICIs with other immunotherapies or with chemotherapy vs standard-of-care chemotherapy as first-line therapy demonstrate a survival advantage of the ICI combination therapy.

×